Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Miller

Showing results (241-250 of 290) with videos related to

Pageof 29
Sort By:
Urologia Internationalis|December 5, 2019
Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate BiopsiesAndreas Maxeiner, Alexander M Nest, Carsten Stephan, et al.
The Canadian Journal of Urology|June 19, 2012
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastasesUlf W Tunn, Amulf Stenzl, Wolfgang Schultze-Seemann, et al.
The Journal of Urology|May 8, 2018
Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate CancerSebastian L Hofbauer, Andreas Maxeiner, Beatrice Kittner, et al.
European Urology|March 18, 2014
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)Manfred Wirth, Teuvo Tammela, Virgilio Cicalese, et al.
Urology|March 26, 2014
Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelixE David Crawford, Neal D Shore, Judd W Moul, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2021
Neoadjuvant and adjuvant end-points in health technology assessment in oncologyNadia Harbeck, Andreas Schneeweiss, Peter Thuss-Patience, et al.
The Journal of Urology|August 29, 2020
Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single CenterRichard E Hautmann, Björn Volkmer, Günther Egghart, et al.
European Radiology|March 29, 2020
Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancerMadhuri M Rudolph, Alexander D J Baur, Matthias Haas, et al.
World Journal of Urology|January 1, 2014
Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladderJan Ebbing, Susanne Mathia, Felix S Seibert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancerJohann Sebastian de Bono, Joaquim Bellmunt, Gerhardt Attard, et al.
Pageof 29

Showing results (241-250 of 290) with videos related to

Sort By:
Pageof 29
Urologia Internationalis|December 5, 2019
Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate BiopsiesAndreas Maxeiner, Alexander M Nest, Carsten Stephan, et al.
The Canadian Journal of Urology|June 19, 2012
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastasesUlf W Tunn, Amulf Stenzl, Wolfgang Schultze-Seemann, et al.
The Journal of Urology|May 8, 2018
Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate CancerSebastian L Hofbauer, Andreas Maxeiner, Beatrice Kittner, et al.
European Urology|March 18, 2014
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)Manfred Wirth, Teuvo Tammela, Virgilio Cicalese, et al.
Urology|March 26, 2014
Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelixE David Crawford, Neal D Shore, Judd W Moul, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2021
Neoadjuvant and adjuvant end-points in health technology assessment in oncologyNadia Harbeck, Andreas Schneeweiss, Peter Thuss-Patience, et al.
The Journal of Urology|August 29, 2020
Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single CenterRichard E Hautmann, Björn Volkmer, Günther Egghart, et al.
European Radiology|March 29, 2020
Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancerMadhuri M Rudolph, Alexander D J Baur, Matthias Haas, et al.
World Journal of Urology|January 1, 2014
Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladderJan Ebbing, Susanne Mathia, Felix S Seibert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancerJohann Sebastian de Bono, Joaquim Bellmunt, Gerhardt Attard, et al.
Pageof 29